Loughborough, UK, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura Medical” or the “Company”), developer of a daily wear non-invasive glucose sensor, and digital healthcare programs is pleased to announce that the Nasdaq Hearings Panel granted the Company’s request for continued listing pursuant to an exception, including certain interim milestones, that ultimately expires on April 1st, 2024, to evidence compliance with all applicable criteria for continued listing on The Nasdaq Capital Market.

英国拉夫堡，2023年12月13日（环球通讯社）--Nemara Medical Inc.（纳斯达克代码：NMRD）（“Nemara Medical”或“公司”），日用无创血糖传感器和数字医疗保健计划的开发商，高兴地宣布，纳斯达克听证会小组批准了该公司根据例外情况（包括某些临时里程碑）继续上市的请求，该协议最终将于2024年4月1日到期，以证明其符合继续在纳斯达克资本市场上市的所有适用标准。

The Company plans to continue with its commercial endeavours while pursuing its plans to ensure timely compliance with the terms of the Nasdaq Hearing Panel’s decision. About Nemaura Medical, Inc. Nemaura Medical, Inc. is a medical technology company developing and wearable diagnostic devices. The company is currently commercializing sugarBEAT® and proBEAT™.

该公司计划继续其商业活动，同时执行其计划，以确保及时遵守纳斯达克听证会小组决定的条款。关于Nemara Medical，Inc.Nemara Medical，Inc.是一家开发可穿戴诊断设备的医疗技术公司。该公司目前正在将sugarBEAT®和proBEAT商业化™.

sugarBEAT®, a CE mark approved Class IIb medical device, is a non-invasive and flexible continuous glucose monitor (CGM) providing actionable insights derived from real time glucose measurements and daily glucose trend data, which may help people with diabetes and pre-diabetes to better manage, reverse, and prevent the onset of diabetes.

sugarBEAT®是一种CE标志批准的IIb类医疗设备，是一种非侵入性和灵活的连续血糖监测仪（CGM），可提供实时血糖测量和每日血糖趋势数据得出的可行见解，可帮助糖尿病患者和糖尿病前期患者更好地管理，逆转和预防糖尿病的发作。

Nemaura Medical has submitted a proposal for a Modular PMA (Premarket Approval Application) application for sugarBEAT® to the U.S. FDA, for its generation II, 24 hour sensor. proBEAT™ is a non-regulated version of sugarBEAT which combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service as a general wellness product as part of its BEAT®diabetes program.

Nemara Medical已向美国FDA提交了sugarBEAT®模块化PMA（上市前批准申请）申请提案，用于其第二代24小时传感器。探针™是sugarBEAT的非监管版本，它将使用人工智能处理的非侵入性葡萄糖数据与数字医疗订阅服务相结合，作为其BEAT®糖尿病计划的一部分，作为一般健康产品。

Additionally, Nemaura Medical launched a beta trial of Miboko, a metabolic health and well-being program using a non-invasive glucose sensor along .

此外，Nemara Medical启动了Miboko的beta试验，这是一项使用非侵入性葡萄糖传感器的代谢健康和福祉计划。